Funding Themes

Funding Themes

The CARB-X 2022-2023 funding rounds have three distinct product themes:

Icons for Oral therapeutics, vaccines for neonatal sepsis, and gonnorrhea products

Icon for Oral Products


Oral therapeutics:

The scope is restricted to oral products with several syndromes and causative agents possible, including:

  • Stepdown for respiratory tract infections caused primarily by Gram-negative pathogens, including antibiotic-resistant strains (see Target Product Profile);
  • Safe therapy for infections caused primarily by Gram-positive organisms, including antibiotic-strains (see Target Product Profile); or
  • Safe therapy for urinary tract infections, including those caused by antibiotic-resistant bacteria (see Target Product Profile).

In all cases, activity against multidrug-resistant organisms on the WHO and CDC bacterial threat lists is essential.


Icon for neonatal sepsis


Vaccines for neonatal sepsis:

The scope is restricted to vaccines focused on the prevention of neonatal sepsis, targeting one or more of the following organisms (see Target Product Profile):

  • Klebsiella pneumoniae (highest priority);
  • Escherichia coli (ETEC or urinary);
  • Acinetobacter baumannii; and
  • Staphylococcus aureus.

While a maternal vaccine is sought, an additional commercial indication may be considered.


Icon for Gonorrhea products


Gonorrhea products:

The scope is open to products that address Neisseria gonorrhoeae, including, for example:

Therapeutic and vaccine products must address both drug-sensitive and drug-resistant scenarios.